Restrepo, Lucas, Stafford, Phillip, Magee, D. Mitch, Johnston, Stephen Albert

Objective: Accurate assessment of Alzheimer’s disease (AD), both presymptomatically and at different disease stages, will become increasingly important with the expanding elderly population. There are a number of indications that the immune system is engaged in AD. Here we explore the ability of an antibody-profiling technology to characterize AD and screen for peptides that may […]

Lewis, John E., McDaniel, H. Reginald, Agronin, Marc E., Loewenstein, David A., Riveros, Jorge, Mestre, Rafael, Martinez, Mairelys, Colina, Niurka, Abreu, Dahlia, Konefal, Janet, Woolger, Judi M., Ali, Karriem H.

Alzheimer’s disease (AD) is a leading killer of Americans, imparts a significant toll on the quality of life of the patient and primary caregiver, and results in inordinate costs in an already overburdened medical system. Prior studies on cholinesterase inhibitors among AD patients have shown minimal amelioration of disease symptoms and/or restoration of lost cognitive […]

Dodel, Richard, Rominger, Axel, Bartenstein, Peter, Barkhof, Frederik, Blennow, Kaj, Förster, Stefan, Winter, Yaroslav, Bach, Jan-Philipp, Popp, Julius, Alferink, Judith, Wiltfang, Jens, Buerger, Katharina, Otto, Markus, Antuono, Piero, Jacoby, Michael, Richter, Ralph, Stevens, James, Melamed, Isaac, Goldstein, Jerome, Haag, Stefan, Wietek, Stefan, Farlow, Martin, Jessen, Frank

Background: Three small trials suggest that intravenous immunoglobulin can affect biomarkers and symptoms of mild-to-moderate Alzheimer’s disease. We tested the safety, effective dose, and infusion interval of intravenous immunoglobulin in such patients.; Methods: We did a multicentre, placebo-controlled phase 2 trial at seven sites in the USA and five in Germany. Participants with probable Alzheimer’s […]